Advertisement
Screener

Shattuck Labs, Inc. (STTK) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value

1.8 / 5 stars · 22/61 Roast Me

Shattuck Labs, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value

Shattuck Labs, Inc. (STTK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $200.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-11

  • Shattuck Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $0.00.
  • Shattuck Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $200.00K.
  • Shattuck Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $0.00.
  • Shattuck Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $0.00.
  • Shattuck Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
  • Shattuck Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $1.70M, a 325.00% increase from fiscal 2023.
  • Shattuck Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $400.00K, a 300.00% increase from fiscal 2022.
  • Shattuck Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $100.00K, a 99.15% decline from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month as first filedShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month as first filedShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month as first filedShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed
2026-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11
$200.00K
10-Q · filed 2026-08-11
$200.00K
derived: sum of 3 quarters · filed 2026-08-11
$200.00K
derived: sum of 4 quarters · filed 2026-08-11
2026-03-31$200.00K
10-Q · filed 2026-05-07
$200.00K
derived: sum of 2 quarters · filed 2026-05-07
$200.00K
derived: sum of 3 quarters · filed 2026-05-07
$200.00K
derived: sum of 4 quarters · filed 2026-08-11
2025-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
$0.00
derived: sum of 2 quarters · filed 2026-03-05
$0.00
derived: sum of 3 quarters · filed 2026-08-11
$0.00
10-K · filed 2026-03-05
2025-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$0.00
derived: sum of 2 quarters · filed 2026-08-11
$0.00
10-Q · filed 2025-11-06
-$200.00K
derived: sum of 4 quarters · filed 2026-08-11
2025-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11
$0.00
10-Q · filed 2026-08-11
-$200.00K
derived: sum of 3 quarters · filed 2026-08-11
-$200.00K
derived: sum of 4 quarters · filed 2026-08-11
2025-03-31$0.00
10-Q · filed 2026-05-07
-$200.00K
derived: sum of 2 quarters · filed 2026-05-07
-$200.00K
derived: sum of 3 quarters · filed 2026-05-07
$1.10M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$200.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
-$200.00K
derived: sum of 2 quarters · filed 2026-03-05
$1.10M
derived: sum of 3 quarters · filed 2026-03-05
$1.70M
10-K · filed 2026-03-05
2024-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$1.30M
derived: sum of 2 quarters · filed 2025-11-06
$1.90M
10-Q · filed 2025-11-06
$2.30M
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30$1.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
$1.90M
10-Q · filed 2025-08-14
$2.30M
derived: sum of 3 quarters · filed 2025-08-14
$2.30M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31$600.00K
10-Q · filed 2025-05-01
$1.00M
derived: sum of 2 quarters · filed 2025-05-01
$1.00M
derived: sum of 3 quarters · filed 2025-05-01
$900.00K
derived: sum of 4 quarters · filed 2025-05-01
2023-12-31$400.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27
$400.00K
derived: sum of 2 quarters · filed 2025-03-27
$300.00K
derived: sum of 3 quarters · filed 2025-03-27
$400.00K
10-K · filed 2025-03-27
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
-$100.00K
derived: sum of 2 quarters · filed 2024-11-14
$0.00
10-Q · filed 2024-11-14
$0.00
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30-$100.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
$0.00
10-Q · filed 2024-08-01
$0.00
derived: sum of 3 quarters · filed 2024-08-01
$0.00
derived: sum of 4 quarters · filed 2024-08-01
2023-03-31$100.00K
10-Q · filed 2024-05-02
$100.00K
derived: sum of 2 quarters · filed 2024-05-02
$100.00K
derived: sum of 3 quarters · filed 2024-05-02
$100.00K
derived: sum of 4 quarters · filed 2024-05-02
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$0.00
derived: sum of 2 quarters · filed 2024-02-29
$0.00
derived: sum of 3 quarters · filed 2024-02-29
$100.00K
10-K · filed 2024-02-29
2022-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$0.00
derived: sum of 2 quarters · filed 2023-11-09
$100.00K
10-Q · filed 2023-11-09
$1.70M
10-Q · filed 2022-11-09
-$15.30M
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
$100.00K
10-Q · filed 2023-08-10
$3.90M
10-Q · filed 2022-08-11
-$15.30M
derived: sum of 3 quarters · filed 2023-08-10
-$24.30M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31$100.00K
10-Q · filed 2023-05-09
$4.10M
10-Q · filed 2022-05-12
-$15.30M
derived: sum of 2 quarters · filed 2023-05-09
-$24.30M
derived: sum of 3 quarters · filed 2023-05-09
-$16.20M
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31-$15.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23
-$24.40M
derived: sum of 2 quarters · filed 2023-02-23
-$16.30M
derived: sum of 3 quarters · filed 2023-02-23
$11.80M
10-K · filed 2023-02-23
$10.80M
10-K · filed 2022-03-15
2021-09-30-$9.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
-$900.00K
derived: sum of 2 quarters · filed 2022-11-09
$27.20M
10-Q · filed 2022-11-09
2021-06-30$8.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
$36.20M
10-Q · filed 2022-08-11
2021-03-31$28.10M
10-Q · filed 2022-05-12
2020-12-31$49.70M
10-K · filed 2022-03-15
2019-12-31$400.00K
10-K · filed 2021-03-16

Similar stocks

Stock NameCountryMarket CapPE Ratio
Neurogene Inc. (NGNE)$0.625B-4.46
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
CorMedix Inc. (CRMD)United States$0.605B3.25
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
Monopar Therapeutics (MNPR)United States$0.598B-34.82
Altimmune, Inc. (ALT)United States$0.593B-6.43
Climb Bio, Inc. (CLYM)United States$0.683B-13.03